Viridian Therapeutics Inc
VRDN
Market Cap$797.15M
Close$
$1.79
86.1% downside
Current Fair Value
86.1% downsideOvervalued by 86.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $797.15 Million |
|---|---|
| Enterprise Value | $339.98 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.31 |
| Beta | 0.0 |
| Outstanding Shares | 62,767,570 |
| Avg 30 Day Volume | 769,823 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.35 |
|---|---|
| PEG | -7.28 |
| Price to Sales | - |
| Price to Book Ratio | 1.84 |
| Enterprise Value to Revenue | 1082.75 |
| Enterprise Value to EBIT | -1.34 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...